Preclinical CRO SBH Sciences is a focused preclinical CRO with a track record of working with over 300 biotech and diagnostic companies, offering cell-based discovery, cytokine and enzyme production, and immunological and analytical services, representing a broad opportunity to become a long-term development partner for early-stage firms.

Extensive Assay Portfolio The company houses the largest US cytokine bioassay collection (330 assays) and runs extensive cytotoxicity testing, biomarker measurement, functional activity testing, in vivo modeling, diagnostics, and kinase screening, enabling cross-selling into multiple stages of drug discovery and lead optimization.

Large-scale capabilities With access to 370 human cancer cell lines for in vitro oncology screening and 11 biomarker platforms including automated ELISA, Luminex, Western blot, and qRT-PCR, SBH Sciences can support clients requiring robust, scalable assay and biomarker workflows to de-risk candidate programs.

Upcoming hepatocyte platform The June 2026 development of a hepatocyte-isolated extracellular vesicles platform for NAFLD/NASH biomarker analysis offers a new high-value service line for hepatology-focused biotech firms and pharmaceutical sponsors seeking liver disease biomarkers and mechanistic insights.

Financial & size cues Revenue range of 10–25 million positions SBH Sciences as a mid-sized partner with potential for growth through expanded service offerings, cross-sell into larger CRO portfolios, and collaboration with mid-to-large biotech firms seeking integrated preclinical support.